ZEAL News and Press, Zealand Pharma A/S From 07/03/23

Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss as compared to 2.6...

Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discove...

Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean of 4.2% from baseline (4.8% placebo-corrected) within one week following a single dose of ZP...

Press Release­­­­­­­ No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906) 1 Up to 40% of people who reached the highest two do...

2023-05-11 14:06:10 ET Zealand Pharma A/S. (ZEAL) Q1 2023 Earnings Conference Call May 11, 2023, 08:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO Henriette Wennicke - CFO David Kendall - CMO Conference Call Part...

Company announcement - No. 20 / 2023 Zealand Pharma Announces Financial Results for the First Quarter of 2023 Positive topline data from obesity portfolio On track for two regulatory submissions targeting rare diseases Strengthened balance sheet with DKK 1.5 billio...

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-...

Press Release– No. 3 / 2023 Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results Copenhagen, Denmark, May 4, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery...

Press release – No. 2 / 2023 Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference Copenhagen, Denmark, April 12, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the dis...

Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO TH...